IP Library Granted Patent US 8,158,157
Granted Patent B2
US 8,158,157 · App. 12/831,811 · Granted Apr 17, 2012

Multi-part substitution infusion fluids and matching anticoagulants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,157
App. No.
12/831,811
Granted
Apr 17, 2012
Kind
B2
Abstract

A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Claims (10)

1. A sterile, two part aqueous substitution infusion fluid comprising:

a first aqueous substitution infusion fluid comprising sodium ions, potassium ions and phosphate ions and excluding calcium ions and magnesium ions; and

a second aqueous substitution infusion fluid comprising calcium ions and magnesium ions, wherein a mixed first aqueous substitution infusion fluid and second aqueous substitution infusion fluid excludes acetate, and wherein the aqueous substitution infusion fluid meets a sterility standard for hemofiltration.

2. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the first aqueous substitution infusion fluid and the second aqueous substitution infusion fluid comprise sodium ions.

3. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 70 mmol/L to about 130 mmol/L of sodium ion.

4. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 0.01 mmol/L to about 5 mmol/L of potassium ion.

5. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 100 mmol/L to about 150 mmol/L of chloride ion.

6. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the first aqueous substitution infusion fluid comprises from about 0.01 mmol/L to about 1.5 mmol/L of the phosphate ion.

7. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the second aqueous substitution infusion fluid comprises from about 2 mmol/L to about 11.5 mmol/L of glucose.

8. The sterile, two part aqueous substitution infusion fluid of claim 1 , wherein the first aqueous substitution infusion fluid comprises from about 0.01 mmol/L of potassium ion to about 5 mmol/L of potassium ion, from about 100 mmol/L to about 150 mmol/L of chloride ion, and from about 0.01 mmol/L to about 1.5 mmol/L of phosphate ion, and wherein the second aqueous substitution infusion fluid comprises from about 10 mmol/L to about 35 mmol/L of calcium ion and from about 2.5 mmol/L to about 20 mmol/L of magnesium ion.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: BAXTER HEALTHCARE SA; BAXTER INTERNATIONAL INC.
To: NIKKISO CO., LTD.
Reel/Frame 032210/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2010
From: EDWARDS LIFESCIENCES CORPORATION
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 024680/0595 →